New hope for kids with psoriasis: oral drug apremilast under study

NCT ID NCT05565560

Ongoing Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This phase 3 trial is testing whether apremilast (Otezla) can safely and effectively treat moderate to severe plaque psoriasis in Japanese children and adolescents aged 6 to 17. The study involves 17 participants who take oral tablets for 16 weeks. The main goal is to see if their skin clears or nearly clears, as measured by a doctor's assessment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apremilast (Otezla)
What this could lead to: If successful, this could provide a new oral treatment option for children and teens with moderate to severe plaque psoriasis that is not controlled by topical therapies.
What could go wrong: This is a small, single-arm study with only 17 participants, so results may not apply broadly. Apremilast can cause side effects like nausea, diarrhea, and mood changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS

Contacts and locations

Locations

Dokkyo Medical University Hospital

Shimotsuga-gun, Tochigi, 321-0293, Japan
Fukuoka University Hospital

Fukuoka, Fukuoka, 814-0180, Japan
Fukushima Medical University Hospital

Fukushima, Fukushima, 960-1295, Japan
Gifu University Hospital

Gifu, Gifu, 501-1194, Japan
Gunma University Hospital

Maebashi, Gunma, 371-8511, Japan
Hokkaido University Hospital

Sapporo, Hokkaido, 060-8648, Japan
Hospital of the University of Occupational and Environmental Health, Japan

Kitakyushu-shi, Fukuoka, 807-8556, Japan
Kanazawa Medical University Hospital

Kahoku-gun, Ishikawa-ken, 920-0293, Japan
Kansai Medical University Hospital

Hirakata-shi, Osaka, 573-1191, Japan
Kindai University Hospital

Osakasayama-shi, Osaka, 589-8511, Japan
Kurume University Hospital

Kurume-shi, Fukuoka, 830-0011, Japan
Mita Dermatology Clinic

Minato-ku, Tokyo, 108-0014, Japan
Nagasaki University Hospital

Nagasaki, Nagasaki, 852-8501, Japan
Nagoya City University Hospital

Nagoya, Aichi-ken, 467-8602, Japan
Nippon Life Hospital

Osaka, Osaka, 550-0006, Japan
Saruwatari Dermatology Clinic

Kagoshima, Kagoshima-ken, 890-0046, Japan
Seibo International Catholic Hospital

Shinjuku-ku, Tokyo, 161-8521, Japan
Shinshu University Hospital

Matsumoto-shi, Nagano, 390-8621, Japan
St Lukes International Hospital

Chuo-ku, Tokyo, 104-8560, Japan
St Marianna University Hospital

Kawasaki-shi, Kanagawa, 216-8511, Japan
Sugai Dermatology Park Side Clinic

Utsunomiya, Tochigi, 321-0954, Japan
Takagi Dermatological Clinic

Obihiro-shi, Hokkaido, 080-0013, Japan
Takamatsu Red Cross Hospital

Takamatsu, Kagawa-ken, 760-0017, Japan
Takeoka Dermatology Clinic

Marugame-shi, Kagawa-ken, 763-0074, Japan
Teikyo University Hospital

Itabashi-ku, Tokyo, 173-8606, Japan
Tokai University Hospital

Isehara-shi, Kanagawa, 259-1193, Japan
Tokyo Medical University Hospital

Shinjyuku-ku, 160-0023, Japan
University Hospital Kyoto Prefectural University of Medicine

Kyoto, Kyoto, 602-8566, Japan
University of the Ryukyus Hospital

Ginowan-shi, Okinawa, 901-2725, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.